For research use only. We do not sell to patients.
GSK-626616
CAS No. : 1025821-33-3
Biological Activity：GSK-626616 is a potent, orally bioavailable inhibitor of DYRK3 (IC50=0.7 nM). GSK-626616 inhibits other members of the DYRK family (e.g., DYRK1A and DYRK2) with similar potency, which is a potential therapy for the treatment of anemia.
Research Area：Cardiovascular Disease
Targets：DYRK
Related Screening Libraries:Bioactive Compound Library Plus;Kinase Inhibitor Library;Protein Tyrosine Kinase Compound Library;Anti-Cardiovascular Disease Compound Library;Orally Active Compound Library;Anti-Obesity Compound Library;Targeted Diversity Library;
Related Small Molecules:Harmine hydrochloride;T025;ID-8;Dyrk1A-IN-2;GNF2133 hydrochloride;ARN25068;Haspin-IN-1;LDN-192960 hydrochloride;CLK-IN-T3;GNF4877;DYRKs-IN-2;JH-XIV-68-3;DYRKs-IN-1 hydrochloride;Protein kinase inhibitors 1 hydrochloride;KH-CB20;Dyrk1A/α-synuclein-IN-2;AZ191;Woodtide;CK2/ERK8-IN-1;DYRK1-IN-1;Dyrk1A-IN-5;ML167;tBID;Dyrk1A-IN-4;Mirk-IN-1;Dyrk1A-IN-1
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
About Us:
- MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use；
- Structurally and synthetically diverse biologically active compounds；
- roduct quality is the key to our success and we take pride in offering only the highest-grade products.；
- We provide HNMR, LC-MS, HPLC, stability testing and activity assays of our products to clients.；
- Product identity, quality, purity and activity are assured by our robust quality control programs and procedures.；
- Customized order volume ranging from milligrams to kilograms scale；
Structurally and synthetically diverse biologically active compounds；
We provide customer-oriented services. To explore more, please contact us at [email protected]. Our team will gladly assist you.
